Literature DB >> 31815839

Acceptability and Feasibility of Using Raltegravir Oral Granules for the Treatment of Neonates in a Low-resource Setting.

Moherndran Archary1,2, Brian Zanoni3, Marc Lallemant4,5, Puckwipa Suwannaprom6, Diana Clarke7, Martina Penazzato8.   

Abstract

BACKGROUND: Raltegravir granules for oral suspension, now recommended by World Health Organization for use in neonates with HIV infection, may be challenging for caregivers because of the multistep preparation required.
METHODS: We evaluated the acceptability and feasibility of preparing granules for oral suspension in a low-to-middle-income country setting. Thirty-four caregivers and 10 health-care workers were enrolled from an HIV clinic in Durban, South Africa. Health-care workers were provided with pictorial instruction booklet, demonstration kit and guidance on preparation of granules for oral suspension. The health-care workers then trained caregivers on the preparation of granules for oral suspension. Caregivers were evaluated during the preparation process and instructed to practice at home with a sample kit and return to the clinic for repeat evaluation 5-7 days later. Caregivers and health-care workers were interviewed and participated in a focus group discussion regarding their experiences.
RESULTS: The median age of the caregivers was 31 years (interquartile range: 9.7); 70% had received secondary-level education, 37% were employed. The median preparation time was 7.95 minutes (interquartile range: 5.08 minutes) and 7.48 minutes (3.55 minutes) at initial and repeated observation, respectively. Major errors were insufficient mixing time and incorrect suspension volume. The average number of errors between the 2 observation time points was significantly reduced at the repeat session (2.5 vs. 0.87, P = 0.023). Most participants found the preparation difficult at first but gained confidence over time.
CONCLUSION: Despite the complexity involved in the preparation of the granules for oral suspension, with practice, this formulation was found to be acceptable and feasible to majority of participants in this low-resource setting. As a result, this formulation was included in the 2018 World Health Organization recommendations for first line in neonates living with HIV.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 31815839     DOI: 10.1097/INF.0000000000002539

Source DB:  PubMed          Journal:  Pediatr Infect Dis J        ISSN: 0891-3668            Impact factor:   2.129


  5 in total

1.  Systems Challenges in Accessing Medicines among Children under Thailand's Universal Health Coverage: A Qualitative Study of a Provincial Public Hospital Network.

Authors:  Rangsan Daojorn; Puckwipa Suwannaprom; Siritree Suttajit; Penkarn Kanjanarat; Prangtong Tiengket; Marc Lallemant
Journal:  Children (Basel)       Date:  2022-04-13

2.  Raltegravir (RAL) in Neonates: Dosing, Pharmacokinetics (PK), and Safety in HIV-1-Exposed Neonates at Risk of Infection (IMPAACT P1110).

Authors:  Diana F Clarke; Edward P Acosta; Mae Cababasay; Jiajia Wang; Anne Chain; Hedy Teppler; Stephanie Popson; Bobbie Graham; Betsy Smith; Rohan Hazra; Kat Calabrese; Yvonne Bryson; Stephen A Spector; Jos Lommerse; Mark Mirochnick
Journal:  J Acquir Immune Defic Syndr       Date:  2020-05-01       Impact factor: 3.771

3.  Optimising neonatal antiretroviral therapy using raltegravir: a qualitative analysis of healthcare workers' and caregivers' perspectives.

Authors:  Leila Katirayi; Carl Stecker; Precious Andifasi; Angela Mushavi; Pradisha Tiwari; Chioniso Jakazi; Talent Maphosa; Viva Thorsen; Mildrate Murandu; Gladys Gombakomba; More Mungati; Lise Denoeud-Ndam; Emilia Rivadeneira; Rachel Weber; Susan Hrapcak
Journal:  BMJ Paediatr Open       Date:  2022-07

4.  A Health Literate Patient-focused Approach to the Redesign of the Raltegravir (ISENTRESS) Pediatric Kit and Instructions for Use.

Authors:  Alexander Mills; Laurie Myers; Casey Raudenbush; David A Vossen; Hedy Teppler; Yanna R Miteva; Suzanne Seeley; Brenda Homony; Walter L Straus
Journal:  Pediatr Infect Dis J       Date:  2022-01-01       Impact factor: 2.129

5.  Gaps in Accessibility of Pediatric Formulations: A Cross-Sectional Observational Study of a Teaching Hospital in Northern Thailand.

Authors:  Prangthong Tiengkate; Marc Lallemant; Pimlak Charoenkwan; Chaisiri Angkurawaranon; Penkarn Kanjanarat; Puckwipa Suwannaprom; Phetlada Borriharn
Journal:  Children (Basel)       Date:  2022-02-22
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.